Last reviewed · How we verify
Infection by Cryptosporidium — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Alinia | NITAZOXANIDE | Romark | Antiprotozoal [EPC] | Anoctamin-1 | 2002-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Romark · 1 drug in Infection by Cryptosporidium
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Infection by Cryptosporidium:
- Infection by Cryptosporidium treatment updates — RSS
- Infection by Cryptosporidium treatment updates — Atom
- Infection by Cryptosporidium treatment updates — JSON
Cite this brief
Drug Landscape (2026). Infection by Cryptosporidium — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-by-cryptosporidium. Accessed 2026-06-11.
Related
- Infection by Cryptosporidium full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing